
BD tools for vaccine combination product developers

BD HypakTM for Vaccines Glass Prefillable Syringe System



Key benefits

- Key specifications adapted to the current needs of vaccine manufacturing³
- Minimized risk of deviation through In-Process Controls implemented at critical steps of the manufacturing process³
- Multi-sourcing network for business continuity
- 30 references available: staked needle or luer tip, different flanges, tip or needle caps, etc.

Stacked needle	Luer
1 mL	1 mL – 1,25 mL 1,5 mL
Cut	Cut – Round Small round
Rigid needle shield	Plastic Rigid Tip Cap (PRTC)
25G – 27G	
5/8'	
	1 mL Cut Rigid needle shield 25G – 27G

^{*} for cut flange format

Experience

- Nearly 3 billion units sold since launch⁴
- Selected by the top 5 vaccine pharmaceutical companies^{5,6}
- BD is uniquely positioned with high volume production capacity delivering hundreds of millions⁴ of BD Hypak™ for Vaccines each year

Availability

- Will benefit from BD long- term capacity extension program with investment of over USD 1.2 billion for ready-to-administer containers for injectable drugs⁷
- Samples available on demand
- Commercial availability to be evaluated against requirements



^{**} BD SCF™: BD Sterile, Clean and ready to Fill

References

- 1. Summative Study Report PHS-15-HPK02 : a simulated study for IFU validation of BD Hypak™ stacked needle and BD Hypak™ PRTC in health care workers (HCWs) and self-injection patients populations
- 2. Visual/cosmetic control, Customer Quality Specification, SC000110
- 3. BD Hypak™ for vaccines needle design verification rationale [internal study]. Pont-de-Claix, FR: Becton, Dickinson and Company; 2013
- 4. BD sales analysis [internal analysis]. Pont-de-Claix, FR: Becton, Dickinson and Company; 2019
- 5. Market analysis and product sales for Vaccines, from 2014 to 2018 [internal analysis]. Pont de Claix, FR: Becton, Dickinson and Company; 2019
- 6. Vaccines Market Leaders, https://www.statista.com/statistics/314562/leading-global-pharmaceuticalcompanies-by-vaccine-revenue/ accessed 4th April 2018
- 7. BD-PS external communication to customers BD to Invest \$1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years https://news.bd.com/2020-12-02-BD-to-Invest-1-2-Billion-in-Pre-Fillable-Syringe-Manufacturing-Capacity-Over-Next-Four-Years/Accessed Dec. 2, 2020

BD Medical

Pharmaceutical Systems
United States

1 Becton Drive
Franklin Lakes, NJ 07417
+1 800 225 3310

Europe

11 rue Aristide-Bergès
38800 Le Pont-de-Claix
France
Phone: +33 4 76 68 36 36 - Fax: +33 4 76 68 35 05
Becton Dickinson France S.A.S - Share capital: 64 719 915 €



RCS Grenoble B 056 501 711

